RE:Direction toward success
Sorry we're losing you as a contributor. Seems you have a lot to say. Let me still temper you kind words for management, with which you seem to have a very amicable relationship...
1. The stock has held it's price for the past 6 months. [No, it has held its price for the past 12 months.] Granted it should be at least double where it is now, as biotech approaching the end of a phase 3 trial usually run up nicely in the last 6 months. But the last 6 months have been a disaster for biotech. Hillary Clinton's tweet in September cut most in half [Bad news in a sector should actually motivate shareholders to flock towards companies with more potential. But hey, no one knows about Spectral, sepsis or any treatment]. We held our ground. This is a strong indicator in the overall sentiment of the shareholders as to the likeliness of success [Share price cannot be an indication of FDA’s future approval or refusal, especially when almost no information is floating around to help potential shareholders estimate their chances their bet.]
2. Management is not pumping. [Management is not talking.] They are clearly confident and focused on the end game [Please management, what would be the end game?] rather than inflating the stock price. [Didn’t you say the SP should be at least double…? Obtaining a fair SP is not “inflating”.] The numbers will follow with success. [If that were always true.]
3. The company clearly has a amicable working relationship with the FDA. [Where do you get that from? Where’s your evidence? FDA is looking at numbers and met criteria, not friendliness of submitters.] Those who followed NRI a while back will know that even with a good product, decisions in the process can go either way. [Let’s hope for future sepsis patients the relationship between Spectral and the FDA remains amicable.] This trial could have been halted and the company sent back to do their own analysis for another trial, but that didn't happen. [This treatment could also have been approved much earlier. The DSMB could have been killed in an accident. All sorts of things could have happened. But if they are not reported and discussed in the public, well how then can Spectral go about financing their hard earned options? Diluting is then the only option.] The trial continued on a modified basis, [Could management or the FDA explain why?] and on top of it all prior results would not be considered. I have never seen that before.
4. There are no other treatments. [There are. Called standard care] Usually aiming for a 30% success rate gets you out of the gate but any rate greater than placebo [Not placebo, standard care] is better than all other treatments. [Tell that to the FDA!]
5. The people who will be deciding if the trial is a success are the same people who already looked at the results and modified the trial based on what they saw as being successful. It is essentially a confirmation of what they saw. [Good thing you do not (?) work for Spectral, as we wouldn’t want the SP to inflate due to all those positive factors!]